PharmGKB Clozapine PK Pathway appears on the cover of Pharmacogenetics and Genomics

The Clozapine Pharmacokinetics Pathway is featured on the cover of September 2018 volume 28 issue 9 of Pharmacogenetics and Genomics. This pathway shows the candidate genes involved in the metabolism of the antipsychotic drug clozapine and was developed by curator Dr Caroline F. Thorn with Professor Daniel Mueller of the Centre for Addiction and Mental Health, Canada.

CYP2D6 genotype to phenotype standardization project - seeking feedback

The assignment of the CYP2D6 metabolizer phenotype based on a subject's genotype is an important aspect of clinical implementation of pharmacogenetics knowledge. Especially for CYP2D6, the genotype-inferred phenotypes vary across laboratories and guidelines. The goal of the CYP2D6 genotype to phenotype standardization project is to harmonize this translation. 

The following consensus was reached by a group of CYP2D6 excepts through a series of surveys:
1) Activity score of 1 should be assigned as CYP2D6 intermediate metabolizer
2) Downgrading the CYP2D6*10 allele from activity score 0.5 to 0.25

We are seeking feedback on the final CYP2D6 genotype to phenotype table, which summaries all CYP2D6 metabolizers assignment based on activity score. 

Information about the project are available here: https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/. Please email any comments to contact@cpicpgx.org by September 27th.